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Abstract
Background: Hypoxia inducible factors (HIFs) are the principal means by which cells upregulate genes in response to
hypoxia and certain other stresses. There are two major HIFs, HIF-1 and HIF-2. We previously found that certain genes are
preferentially activated by HIF-2. One was protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1). PTPRZ1 is
overexpressed in a number of tumors and has been implicated in glioblastoma pathogenesis.
Methodology/Principal Findings: To understand the preferential activation of PTPRZ1 by HIF-2, we studied the PTPRZ1
promoter in HEK293T cells and Hep3B cells. Through deletion and mutational analysis, we identified the principal hypoxia
response element. This element bound to both HIF-1 and HIF-2. We further identified a role for ELK1, an E26 transformation-
specific (Ets) factor that can bind to HIF-2a but not HIF-1a, in the HIF-2 responsiveness. Knock-down experiments using
siRNA to ELK1 decreased HIF-2 activation by over 50%. Also, a deletion mutation of one of the two Ets binding motifs
located near the principal hypoxia response element similarly decreased activation of the PTPRZ1 promoter by HIF-2. Finally,
chromatin immunoprecipitation assays showed binding of HIF and ELK1 to the PTPRZ1 promoter region.
Conclusions/Significance: These results identify HIF-binding and Ets-binding motifs on the PTPRZ1 promoter and provide
evidence that preferential activation of PTPRZ1 by HIF-2 results at least in part from cooperative binding of HIF-2 and ELK1
to nearby sites on the PTPRZ1 promoter region. These results may have implications in tumor pathogenesis and in
understanding neurobiology, and may help inform the development of novel tumor therapy.
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Introduction
Oxidative metabolism is essential for many processes in
mammalian cells, and cells must rapidly respond to the stress of
reduced oxygen or face irreversible cell damage and death.
Organisms respond to hypoxia through a number of adaptations,
such as increased glycolysis, angiogenesis, and erythropoeisis [1].
Many of these adaptations are mediated through the activation of
specific genes by hypoxia-inducible factors (HIFs) [2]. HIFs are
heterodimers composed of either HIF-1a or HIF-2a combined
with constitutively expressed HIF-1b to form HIF-1 and HIF-2,
respectively [3]. HIF-1a and HIF-2a are constitutively expressed,
but under normoxic conditions are hydroxylated at specific proline
residues, resulting in ubiquitination through the interaction with
von Hippel-Lindau factor protein (pVHL) and proteosomal
degradation. Under hypoxic conditions, this proline hydroxylation
is inhibited, leading to their rapid accumulation and binding to
HIF-1b to form active HIFs. Other stimuli such as oxidative stress
may also increase HIF levels [4,5]. HIFs activate hypoxia-
responsive genes by binding to specific sequences in their promoter
regions called hypoxia-responsive elements (HRE); a number of
HRE have been analyzed and the consensus sequence is 59-
RCGTG-39, where R is A or G, although variants have been
reported[4]. Most functional HRE also contain an adjacent
element, termed the ancillary sequence.
There is emerging evidence that HIFs are important in
tumorigenesis, in part through their ability to induce angiogenesis
[6,7,8]. Moreover, von Hippel-Lindau (VHL) syndrome, an
inherited disorder caused by a mutation in the pVHL gene that
leads to elevated HIF levels, is associated with the development of
a number of tumors, especially renal cell carcinoma or
pheochromocytoma [9,10].
A number of initial studies suggested that in general, HIF-1 and
HIF-2 do not differ with regard to their target genes. However,
more recent studies in our lab and elsewhere showed that certain
genes are differentially activated by HIF-1 and HIF-2
[11,12,13,14,15,16]. Studying these effects by microarray in
HEK293T cells, we identified 56 genes that were upregulated
by hypoxia and/or by HIFs [11]. Fourteen of these genes were
preferentially activated by HIF-1 and 10 were preferentially
activated by HIF-2. One HIF-2-specific gene was protein tyrosine
phosphatase, receptor-type, z polypeptide 1 (PTPRZ1), also called
receptor protein tyrosine phosphatase beta (RPTP-b). PTPRZ1
was upregulated about 6 fold by HIF-2a, but not by HIF-1a. HIF-
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PCR. Interestingly, like most of the HIF-2-specific genes identified
in this study, PTPRZ1 was only minimally upregulated by
hypoxia. PTPRZ1 encodes for several additional proteins by
variable splicing, including RPTPb short form, phosphacan, and
phosphacan short isoform [17,18].
PTPRZ1 is preferentially expressed in the central nervous
system, and has been shown to play a role in recovery from
demylenating lesions [19]. Moreover, PTPRZ1 is overexpressed in
a number of tumors, including hepatocarcinoma, renal carcinoma,
and glioblastoma [20]. Its has been most studied in glioblastoma,
where there is evidence that it plays a role in tumor pathogenesis
and may be a target for therapy [20,21,22,23]. However, relatively
little is known about the mechanisms controlling PTPRZ1
expression. In this paper, we dissected the molecular basis for
the upregulation of PTPRZ1 by HIF-2 and show that ELK1, a
member of the Ets family of transcription factors, is involved in its
regulation.
Results
Identification of Functional HREs in the PTPRZ1 Promoter
To investigate the molecular basis for the regulation of PTPRZ1
expression and in particular its upregulation by HIF-2, but not
HIF-1, we analyzed the PTPRZ1 promoter sequence for HRE
consensus sequences [4] and identified five potential HREs
(Figure 1). The first, (HRE1) is encoded in 59-.39 direction on
the sense strand while the other four (HREs 2–5) are encoded in
the 59-.39 direction on the antisense strand (HRE1; -973-968,
HRE2; -447-452, HRE3; -294-299, HRE4; -130-138, and HRE5;
-25-30) (Figure 1). These HREs all contain the consensus core
HRE motif RCGTG (or a CCGTG variant) on either the positive
or negative strand [4]. Nearly all HREs have this consensus motif,
although not all such sequences mediate up-regulation by HIFs
[4,24]. To study the role of these potential HREs, a PTPRZ1
luciferase reporter promoter construct (22138 to +57) containing
the five putative HREs was prepared. In addition, sequential
deletion of this promoter was carried out yielding promoters of
1655 bp, 1059 bp, and 250 bp (Figure 1). The three longest
promoters contain the first 57 base pairs of exon 1 of PTPRZ1, but
this region was not retained in the 250 bp promoter.
The PTPRZ1 promoter constructs were transiently transfected
into HEK293T or Hep3B cells along with plasmids encoding HIF-
1a, HIF-2a, or their degradation-resistant forms (drHIF-1a or
drHIF-2a). HIF accumulation in the nucleus of the cells following
transfection with these plasmids was confirmed by Western blot
analysis of nuclear extracts. Higher levels of HIF-1a and HIF-2a
accumulated in these cells following transfection as compared to
hypoxia and the levels were even greater when the degradation-
resistant plasmids were utilized (results not shown). When the
PTPRZ1-2138 promoter was cotransfected with plasmids encod-
ing HIF-1a or drHIF-1a, there was little or no increase in
promoter activity in either Hep3B or 293T cells (Figure 2). By
contrast, co-transfection with HIF-2a or drHIF-2a increased the
promoter activity 7-10 fold in Hep3B cells and 10–14 fold in
HEK293T cells. Consistent with the results of our previous
microarray study of HEK293T cells[11], little or no increase in
PTPRZ1-2138 promoter activity was observed when the cells were
exposed to hypoxia (results not shown). As a control, we carried
out a similar experiment using the VEGF promoter, which is
responsive to both HIF-1a and HIF-2a [11,12,25]. The VEGF
promoter was upregulated 5 fold or more by HIF-1a, drHIF-1a,
HIF-2a, and drHIF-2a (Figure 2C).
To narrow down the region of the PTPRZ1 promoter
mediating HIF-2a-specific activation, experiments were carried
out with truncated forms (PTPRZ1-1655, PTPRZ1-1059,
PTPRZ1-250). Co-transfection of HIF-1a or drHIF-1a-encoding
plasmids had little effect on these promoters in Hep3B cells
(Figure 3A). By contrast, co-transfection with HIF-2a or drHIF-
2a-encoding plasmids increased promoter activity in PTPRZ1-
1655 by 23 fold, and upregulation was also seen with the shorter
constructs (Figure 3A). Similarly, in HEK293T cells, all the
promoters were activated to a greater degree by HIF-2a as
compared to HIF-1a (Figure 3B), although the relative specificity
of up-regulation by HIF-2a was not as clear cut. In both cell lines,
the shortest PTPRZ1 promoter, PTPRZ1-250, was still preferen-
Figure 1. PTPRZ1 luciferase promoter constructs showing the location of the potential hypoxia response elements (HRE) and Ets
binding sequences (EBS). Each HRE is denoted as a square and each EBS as a plus sign. The TATA box and the ATG start site are indicated in the
PTPRZ1-250 promoter. Each promoter construct extends 57 bp into the PTPRZ1 coding region prior to the luciferase (LUC) sequence except for the
PTPRZ1-250 promoter, which stops at the ATG. The HRE consensus sequences and direction of each HRE are also indicated. The core HRE sequences
are: HRE1, CCGTG; HRE2, CACGC; HRE3, CACGC; HRE4, CACGCACG; HRE5, CACGG.
doi:10.1371/journal.pone.0009641.g001
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leading to preferential HIF-2a activation were contained within
this region.
Mutational Analysis of PTPRZ1-250 Promoter
The PTPRZ1-250 sequence contained two putative HREs:
HRE4 and HRE5. To further identify the functional HRE(s) that
mediated the response to HIF-2a, we performed site-directed
mutagenesis of these two HREs. A 3 bp mutation of HRE4 or
HRE5 was introduced into each promoter to generate PTPRZ1
mutants M4 and M5 respectively (Figure 4A). HRE4 is a near-
tandem HRE, and the mutations were designed to affect both
consensus sequences. Mutation of HRE5 did not affect PTPRZ1-
250 promoter activity in Hep3B cells but led to a modest reduction
of promoter activity in HEK293Tcells (Figure 4B). By contrast,
mutation of HRE4 virtually eliminated HIF-2a-induced up-
regulation of the PTPRZ1-250 promoter in both Hep3B and
HEK293T cells (Figure 4B). In subsequent experiments utilizing
larger promoter constructs, the HRE4 mutation also led to a
greater loss in activity than the HRE5 mutation (Figures 4C and
4D). These results indicate that HRE4 is a main contributor to the
response of the PTPRZ1 promoter, although there may also be a
contribution from HRE5 as well as other potential HREs.
Functional Binding of HIF to the PTPRZ1 Promoter
To assess the binding of HIF-1 and HIF-2 to HRE4,
electrophoretic mobility shift assays were performed using nuclear
extracts from HEK293T cells exposed to normoxia, hypoxia, or
transfected with HIF-1a or HIF-2a in normoxia (Figure 5). The
DIG-labeled oligo probe containing HRE4 formed a complex with
nuclear extracts from hypoxic, HIF-1a-transfected, and HIF-2a-
transfected HEK293T cells, but not with extracts from normoxic
HEK293T cells. This complex migrated to a position similar to
that previously identified for hypoxic nuclear extracts with a 30-bp
erythropoietin (EPO) oligo probe containing an HRE [26] (data
not shown). HRE4 complex formation with HIF-1a and with HIF-
2a was inhibited by competition with unlabeled wild-type HRE4
oligonucleotide at 50 and 100 times the concentration of labeled
probe, but not by identical concentrations of mutant HRE4
oligonucleotides, suggesting that binding was specific to the HRE4
sequence (Figure 5). These data demonstrate that both HIF-1a
and HIF-2a can bind to HRE4 of the PTPRZ1 promoter and that
the HIF-2a activation specificity is not simply a function of
differential binding of the HIFs to the HRE.
ELK1 Is Required for Optimal HIF-2a Activation of the
PTPRZ1 Promoter
The Ets transcription factor ELK1 has previously been reported
to physically interact with HIF-2a protein, but not HIF-1a protein
[13] and to facilitate the activation of CITED2, a gene whose
response to hypoxia is primarily mediated by HIF-2a [13].
Knockdown of ELK1 by ELK1 siRNA significantly reduced
hypoxic induction of CITED2. Similarly, interaction between
HIF-2a and ETS1 was reported to be required for full
transcriptional activation of FLK1gene, another HIF-2a-specific
gene, in endothelial cells [14]. In another study, it was shown that
HIF-2a cooperates with ETS1 transcription factor to activate the
VE-Cadherin promoter [16].
Figure 2. Comparison of the activation of the PTPRZ1-2138
luciferase reporter by HIF-1a and HIF-2a and their degrada-
tion-resistant forms. (A) Hep3B or (B) HEK293T cells were co-
transfected with 300 ng of PTPRZ1-2138 promoter and 50 ng of an
internal b-gal control plasmid in the presence of 250 ng of an
expression plasmid encoding HIF-1a, drHIF-1a, HIF-2a, drHIF-2a,o r
pcDNA3.1 expression plasmid control. Values are expressed as fold
increase over the reporter lacking expression vector (pcDNA3.1) and
represent the mean of triplicate determinations in one representative
experiment out of three with similar results. Error bars denote the
standard deviations. (C) Results obtained with a VEGF luciferase reporter
control plasmid under the same conditions.
doi:10.1371/journal.pone.0009641.g002
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HIF-2a might also involve an Ets, we examined the promoter
sequence for putative Ets binding sites (EBS) using Genomatix
software (Genomatix Software GmbH, Munchen, Germany).
Several potential sites were identified, of which two, named here
EBS4 (ggagcgaaGGAAatgttttt) and EBS5 (gaccgtctGGAAatgc-
gaatc) were present within the 250 bp promoter construct
(Figure 1). Both contained the core Ets recognition motif 59-
GGA(A/T)-39[27], shown in capital letters. EBS4 was located
between HRE4 and HRE5 and EBS5 was located just downstream
of HRE5. As ELK1 has previously been shown to bind to HIF-2
and be involved in hypoxic gene activation [13], we hypothesized
that ELK1 might play a role in PTPRZ1 activation by HIF-2a.
To test this hypothesis, siRNA experiments were performed on
HEK293T cells using the PTPRZ1-250 bp promoter with a
luciferase reporter. (Hep3B cells could not be utilized because of
toxicity from the siRNA transfection reagent). Western blot
analysis indicated that transfection of HEK293T cells with
ELK1 siRNA resulted in a substantial reduction in ELK1 protein
as compared to cells treated with scrambled siRNA or b-actin
siRNA controls (Figure 6A). Also, real-time RT-PCR analysis
indicated that relative levels of ELK1 mRNA decreased more than
90% following treatment with ELK1 siRNA (Figure 6B), and this
was similar to the decrease observed for b-actin in cells treated
with b-actin siRNA as a control (Figure 6C). When PTPRZ1-250-
transfected HEK293T cells were co-transfected with HIF-2a in
the presence of ELK1 siRNA, luciferase reporter activity
decreased more than 75% as compared to cells transfected with
HIF-2a alone or HIF-2a in combination with a scrambled siRNA
control (Figure 6D) or to GAPDH siRNA control (results not
shown). Taken together, these data suggest that ELK1 plays a role
in the activation of PTPRZ1 by HIF-2a.
To explore this further, we assessed the effects of mutations in
the EBS4 and EBS5 Ets binding sites. Four base-pair deletions
Figure 3. Comparison of the activation of truncated forms of PTPRZ1 luciferase reporter by HIF-1a and HIF-2a and their
degradation-resistant forms. (A) Hep3B or (B) HEK293T cells were co-transfected with 300 ng of each PTPRZ1 promoter and 50 ng of an internal
b-gal control plasmid in the presence of 250 ng of an expression plasmid encoding HIF-1a, drHIF-1a, HIF-2a, drHIF-2a, or pcDNA3.1control. Results
are expressed as in Figure 2.
doi:10.1371/journal.pone.0009641.g003
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EBS5 within the 250 bp promoter construct and the activation by
HIF-2a or HIF-1a transfection tested in the luciferase assay. The
4-bp deletion of the EBS4 core sequence decreased the activation
of the promoter by HIF-2a by about half, as compared to the wild-
type (WT) promoter sequence, while it had no appreciable effect
on the activation by HIF-1a. By contrast, the 4-bp deletion of the
EBS5 core sequence did not affect the promoter activation by
HIF-2a or HIF-1a.
To further assess the potential binding of HIF proteins and
ELK1 in the region near EBS4, we utilized chromatin immono-
precipitation, amplifying the region that included HRE4, HRE5,
EBS4, and EBS5. Using anti-HIF antibodies, we found that both
HIF-1a and HIF-2a could bind in the promoter region of
PTPRZ1 (Figure 7B). These results are consistent with the finding
by electrophoretic mobility shift assay that either HIF-2a or HIF-
1a could bind to HRE4. In addition, using anti-ELK1 antibody,
we found that ELK1 bound in the same region. Collectively, these
Figure 4. Effect of HRE4 and HRE5 mutations in the PTPRZ1 promoter on the response to HIF-2a. (A) DNA sequences for the HRE4 and
HRE5 WT and mutant constructs. The underlined region indicates the location of the putative HREs, and bold letters indicate the mutations from WT
for each mutant construct. (B–D) HEP-3B and HEK293T cells were co-transfected with plasmids encoding HIF-2a and either the wild-type reporter
promoter (WT), the HRE4 mutant reporter promoter (M4), or the HRE5 mutant reporter promoter (M5). WT reporter cotransfected without HIF
(pcDNA3.1) was used as a control. (B) PTPRZ1-250. (C) PTPRZ1-1655. (D) PTPRZ1-2138. Values were expressed as in Figure 2; shown are the mean and
standard deviation of triplicate determinations.
doi:10.1371/journal.pone.0009641.g004
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contributes to the induction of PTPRZ1 by HIF-2a.
Discussion
In our initial study of the effects of HIFs on gene activation,
PTPRZ1 was identified as one of 10 genes that were substantially
upregulated by HIF-2a but not by HIF-1a [11]. In the current
study, we sought to understand the molecular regulation of
PTPRZ1 expression and in particular the basis for its HIF-2-
specificity. In each of two cell lines studied, Hep3B (derived from
human hepatoma cells) and HEK293T (derived from human
embryonic kidney cells), substantially more PTPRZ1 promoter
activity, as assessed using a luciferase reporter assay, was observed
in response to HIF-2a as compared to HIF-1a. We found that
much of the HIF-2-induced activation of PTPRZ1 could be
attributed to HRE4, a near-tandem HRE on the antisense strand
of the promoter region with the sequence TACGCACGCACGA.
Furthermore, we found evidence that cooperative interaction
between HIF-2a and the Ets factor ELK1 played a major role in
mediating the HIF-2-specificity of PTPRZ1.
Since the discovery of HIF-2a [28,29], researchers have
explored the question of what role this seemingly redundant
factor may have. Initial studies suggested that HIF-2 activated the
same genes as HIF-1, but that its expression was largely limited to
certain tissues and organs, particularly endothelial cells, renal
tissue, lungs, heart, and small intestine [28,29,30]. More recent
studies revealed that certain genes were preferentially or selectively
activated by HIF-1 or HIF-2. Hu et al. found that hypoxic
induction of several genes associated with glycolysis was selectively
mediated by HIF-1 [12]. Our group and others subsequently
found that a number of genes were preferentially upregulated by
HIF-2, including CITED2, EPO, PAI-1, Tie2/TEK, VEGF
receptor 2, and LOX [7,11,13,14,16].
This leads to the question of the mechanism for HIF-2
specificity. A number of functional HRE have been sequenced,
and no obvious differences in the core HRE sequences between
HIF-1 and HIF-2 target genes have emerged [4]. Our finding that
the sequence of PTPRZ1 HRE4 is similar to other HREs and that
this region bound to both HIF-1a and to HIF-2a is consistent with
the concept that HIF-specificity is not mediated by the HRE core
sequence. Several recent reports have provided evidence that HIF-
2-specificity of certain genes can be conferred by cooperative
binding of HIF-2a and members of the Ets family of transcription
factors to elements in the genes’ promoter regions [13,14,16,31].
In particular, it was reported that the HIF-2-preferential activation
of Flk-1, VE-cahedrin, and endosialin is mediated by an
interaction between HIF-2a and ETS1, and that the HIF-2-
preferential activation of CITED2 is mediated by an interaction
between HIF-2a and ELK1 [13,14,16,31]. We found that a
250 bp region of the PRPTZ1 promoter region that maintained
HIF-2-specificity contained two putative Ets factor binding sites,
that the HIF-2-responsiveness of this region could be impaired by
siRNA to ELK1, that the HIF-2 responsiveness could be impaired
Figure 5. HIF-1 and HIF-2 bind to PTPRZ1 oligonucleotide probes containing HRE4. DIG-labeled synthetic oligonucleotide containing
HRE4 was incubated with nuclear extracts (NE) from normoxic (N), 16 hour hypoxic (H) or HIF-transfected (HIF-1a or HIF-2a) HEK293T cells and
analyzed on a non-denaturing polyacrylamide gel. Where indicated, unlabeled wild type (WT) or mutant (Mut) oligonucleotides (at 50x and 100x of
the labeled probe) were added to the binding reaction. Protein-DNA complexes were separated, blotted to a nylon membrane, and probed with anti-
digoxigenin antibody conjugated to alkaline phosphatase. Comp denotes unlabeled probe used for binding competition. The sequence of the probe
and WT and Mut competing oligonucleotides used is shown at the bottom. WT HRE4 sequence is underlined, and nucleotide changes in the Mut
sequence are shown in bold. The positions of the DIG-labeled HIF complexes and free probe are indicated with arrows.
doi:10.1371/journal.pone.0009641.g005
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that HIF-2a and ELK1 could both bind to this region in proximity
to each other. Also, ELK1 has previously been shown to physically
interact with HIF-2a (but not HIF-1a) [13], and taken together,
these results provide evidence that the HIF-2-specificity of
PTPRZ1 is mediated at least in part by cooperative binding of
HIF-2 and ELK1 to nearby sites in the PTPRZ1 promoter. It is
possible that ELK1 binding to the promoter facilitates the binding
of HIF-2a, or that these two factors work in concert to facilitate
binding of another factor that provides optimal activation of
PTPRZ1 transcription. These findings do not exclude a
contribution from other Ets factors; due to the conservation of
sequences within the ETS domain, Ets proteins all bind to similar
DNA binding sequences, and the DNA sequence of EBS4 predicts
it may also have binding to another Ets factor, ETS2 (references
[27] and [32] and Genomatix Software). Nonetheless, the
abrogation of the HIF-2a induction of PTPRZ1 by siRNA to
ELK1 provides evidence that ELK1 plays an important role in the
HIF-2a responsiveness.
It is noteworthy that in our original study using HEK293T cells,
PTPRZ1 was activated by HIF-2a transfection but not by hypoxia
[11]. This may in part reflect the fact that HEK293T cells exhibit
relatively small increases of HIF-2 when exposed to hypoxia. At
the same time, there is emerging evidence that stresses other than
hypoxia may mediate increases in genes that are normally
considered hypoxia responsive. For example, it has been reported
that lysyl oxidase like 2 (LOXL2) is upregulated by high cell
density through a mechanism that involves ETS1 [33]. Also,
expression of HIF-2a, but not HIF-1a, has been observed in well
oxygenated neuroblastoma tissue [34]. Interestingly, PTPRZ1 has
recently been reported to be induced by chronic oxidative stress
[35]. Perhaps related to this finding is the recent report that Sirtuin
1 (Sirt1), a deacetylase that is produced in response to redox stress,
can enhance the activity of HIF-2a (but not HIF-1a) [5]. Thus, it
is possible that under redox stress, Sirt1 enhances HIF-2a activity,
which in turn promotes the overexpression of PTPRZ1.
PTPRZ1 is expressed predominantly in the central nervous
system (CNS) during development and involved in signal
transduction and recovery from demylenating lesions [19,36]. In
addition, PTPRZ1 and its ligand pleiotrophin are overexpressed in
human glioblastoma [22] and there is substantial evidence that
these proteins play an important role in the pathogenesis of this
cancer (for review see [18]). Further evidence for the importance
of PTPRZ1 in glioblastoma is provided by the finding that down
regulation of PTPRZ1 by siRNA suppresses glioblastoma growth
in vitro and in vivo [23]. Moreover, a monoclonal antibody to
PTPRZ1 has been shown to delay tumor growth in a glioblastoma
model [20]. There is also recent evidence that PTPRZ1 is
upregulated and may play a role in the pathogenesis of a wide
variety of tumors [20].
At the same time, there is increasing evidence that HIF-2 plays
an important role in the pathogenesis of many tumors. Tumors
require neovasculature to grow above a minimal size, or else they
outstrip their oxygen supply, and HIFs stimulate the production of
VEGF and other crucial vascular growth factors [6,37]. Patients
with VHL syndrome, who have increased levels of HIFs, develop a
number of tumors including renal cell carcinoma [9]. Interestingly,
there is evidence that tumorigenesis of renal cell carcinoma is
associated with overexpression of HIF-2a, while HIF-1a inhibits
tumor growth [10,25,38,39]. Also, HIF-2a has recently been
Figure 6. siRNA to ELK1 inhibits PRPRZ1 activation. (A) Immunoblotting analysis for ELK1, b-Actin, and GAPDH in HEK293T cells transfected
with ELK1 scrambled siRNA (60 nM), b-Actin siRNA (60 nM), or ELK1 siRNA (60 nM). (B) ELK1 mRNA as determined by quantitative RT-PCR from
HEK293T cells 48 hours after transfection with ELK1 scrambled siRNA, b-Actin siRNA, or ELK1 siRNA. (C) b-Actin mRNA under similar conditions. (D)
PTPRZ1-250 promoter activity in HEK293T cells following transfection with HIF-2a plasmid alone or HIF-2a plasmid and either scrambled siRNA, or
ELK1 siRNA. Data is presented as fold induction over vector control after normalization to b-gal. Bars represent mean and standard deviation of 3
determinations.
doi:10.1371/journal.pone.0009641.g006
Induction of PTPRZ1 by HIF-2a
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9641shown to enhance cell-cycle progression and tumorigenesis by
promoting c-Myc transcriptional activity, while HIF-1a opposes c-
Myc [15,40].
The HIF-2-specific upregulation of PTPRZ1 may provide yet
another mechanism by which HIF-2, but not HIF-1, promotes
tumorigenesis in a variety of tumors. As noted above, while
PTPRZ1 expression was initially thought to be largely limited to
the central nervous system, it has been shown that PTPRZ1 is
overexpressed in a variety of tumors, including hepatocarcinoma
and renal carcinoma [20,41,42]. Also, PTPRZ1 has been shown to
activate the b-catenin pathway, which can promote tumorigenesis
[35,43]. The potential role of HIF-2 upregulation of PTPRZ1 in
renal cell carcinoma of particularly intriguing, as VHL is
associated with renal cell carcinoma and there is evidence that
HIF-2 is more important than HIF-1 in the renal cell carcinoma
tumorigenesis in this setting [38]. Taken together, these results
suggest that activation of PTPRZ1 by HIF-2a and ELK1 may be
an important step in the pathogenesis of a variety of tumors.
Further study of these relationships may help inform strategies to
prevent and treat these tumors.
Material and Methods
Cell Culture
HEK293T and Hep3B cell lines were obtained from ATCC
(American Type Culture Collection, Manassas, VA)where they
were authenticated by short tandem repeats and karyotyping, and
frozen in liquid nitrogen. After thawing, the cell lines were
maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum (Heat inactivated, Hyclone, Logan,
Utah) and penstrep/glutamine (Invitrogen Corp, Carlsbad, CA),
and used within 6 months. Cells were incubated in 95% air and
5% CO2 (normoxia) or 1% O2 and 5% CO2 (hypoxia) at 37uCi n
a standard tissue culture incubator.
Plasmid DNA Construction and Site-Directed
Mutagenesis
Expression plasmids encoding human HIF-1a (pHAHIF1a-
pcDNA3) and a degradation-resistant form of HIF-1a (drHIF-1a)
were gifts from Eric Huang (NCI, NIH) [44]. An expression plasmid
encoding human HIF-2a (hEPAS1-pcDNA3) was a gift from Steven
L. McKnight (University of Texas) [28]. A plasmid encoding a
degradation-resistant form of HIF-2a (drHIF-2a) was created by
mutating prolines 405 and 531 of HIF-2a to alanine. All plasmids
were purified with a Qiagen Maxiprep kit (Qiagen, Valencia, CA),
and inserts were verified by restriction enzyme mapping and DNA
sequencing. PTPRZ1 gene promoter luciferase reporter constructs
were created containing regions spanning nucleotides 22138bp,
21655bp, or 21059bp upstream to +5 7 b pe x o nI( F i g u r e1 ) .D N A
fragments were amplified from human genomic DNA (Cat#G304A
Promega Madison WI) by PCR with 59primers PTF1, PTF2, PTF3
(59-CAGTGGTACCGTTTGTCACAGTCTGACCC-39,5 9-CAG-
TGGTACCCTGCCATTAGCTTGCACA-39,5 9-GAGCGGTA-
CCGCATACCCTTCAATCAAGC-39)a n d3 9primer PTR2( 59-
TAGTAAGATCTACCGATCCCGGAGCTGAA-39) which con-
tain Kpn1/BglII sites. PCR fragments were purified and cloned into
the corresponding sites of the luciferase reporter vector pGL3basic
(Promega) to generate three different PTPRZ1 promoter reporter
plasmids (Figure 1). A PTPRZ1-250 promoter was created and
amplified by PCR using PTPRZ1-1655 plasmid DNA as template
with 59primers PTFc (59-AGTCATGCTAGCGTGCGGCTTTC-
TCCAGAT-39)a n d3 9primer PTR3 (59-ATGATACTCGAGTTC-
CAGACGGTCTGCGGC-39), which contain NheI/XhoI sites.
This PCR fragment ends before the ATG. PCR fragments were
inserted into the corresponding sites of pGL3basic. Plasmid DNAs
PTPRZ1-2138M4, -1655M4, -1059M4 and -250M4 expressing a
mutagenized HRE (HRE4) were constructed using PCR-based
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA). The primers contain the mutated HRE4 sequences, 59 primer
(5 9-CACACAAACACACATACGCGCATACGATCTCACTTC-
Figure 7. Role of EBS4 in the activation of PTPRZ1 promoter by
HIF-2a. (A) Effects of EBS4 or EBS5 deletion on the response of the
PTPRZ1 promoter to HIF-2a. HEK293T cells were co-transfected with
300 ng of PTPRZ1-250WT, EBS4D, or EBS5D promoters and 50 ng of a
internal b-gal control plasmid in the presence of 250 ng of an
expression plasmid encoding HIF-1a, HIF-2a or pcDNA3.1 empty
control vector. Results are expressed as in Fig 2. (B). Binding of HIF-
2a and HIF-1a to the PTPRZ1 promoter in the region near EBS4, EBS5,
HRE4, and HRE5 in vivo. The chromatin immunoprecipitation assay was
performed with HEK293T cells transfected with HIF-1a or HIF-2a
respectively. Pre-cleared chromatin was immunoprecipitated with anti-
HIF-2a or anti-HIF-1a antibody or normal rabbit IgG. After reversal of
cross-linking, the DNA was analyzed by PCR. The primer set for PCR
were designed to cover the EBS4, EBS5, HRE4, and HRE5 sites (C)
Binding of ELK1 to the PTPRZ1 promoter. Experiment performed as in
7B except that the HEK293T cells were transfected with an Elk-1
expression vector and anti-ELK1 antibody or normal rabbit IgG was
utilized.
doi:10.1371/journal.pone.0009641.g007
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GATCGTATGCGCGTATGTGTGTTTGTGTG-39). This mu-
tant plasmid DNA contained a 3 nucleotide substitution (underlined)
in the HRE4 element (from GCACGCACG to GCGCATACG).
Reactions were performed for 16 cycles at 95uC for 30 seconds, 55uC
for 1 min and 68uC for 7 min. PCR products were incubated with
DpnI enzyme at 37uC for 2 hrs to digest the parental vector. DNA
was used to transform XL1-Blue competent cells. Constructs were
confirmed by DNA sequencing. Plasmid DNA PTPRZ1-2138M5, -
1655M5, -1059M5 and -250M5 with a mutagenized HRE5 were
generated by using the same technique and primer set sequences as
follows: 59 primer (59-GAAGCAGAGGAGCCGCTTTGCGA-
GGGGCCGCAGA-39), and 39 primer (59-TCTGCGGCC-
CCTCGCAAAGCGGCTCCTCTGCTTC-39) (HRE5 wild type
sequences were mutated from GCACG to GCTTT). Plasmid DNA
PTPRZ1-EBS4D and EBS5D with deletion of Ets-binding core
motifs GGAA were generated by using the same technique and
primer set sequences as follows: 59 primer (59 CAAAAAAAA-
CATTTCGCTCCCCCTCCCTCTCC 39), and 39 primer (59 GG-
AGAGGGAGGGGGAGCGAAATGTTTTTTTTG 39). EBS5D
primer sets were: 59 primer (59 ACGGCGAGGGGCCGCACTC-
GAGATCTGCGATCT 39), and 39 primer (59 AGATCGCA-
GATCTCGAGTGCGGCCCCTCGCCGT 39).
Transfection and Luciferase Reporter Assays
Cells were transfected as described [11] except that Fugene6
transfection reagent (Roche, Indianapolis, IN) was utilized. For
luciferase reporter experiments, 1.5610
5 of HEK293T cells or
0.5610
5 Hep3B cells/well were plated in a 12 well plate and the
following day were co-transfected with 300 ng/well of reporter
plasmid DNA and 250 ng/well of a HIF or a control (pcDNA3.1)
expression plasmid in the presence of 50 ng of an internal control
plasmid DNA, pSV-b-gal (Promega) to normalize transfection
efficiency. After transfection, cells were incubated in normoxia for
48 hrs. Cells were then washed with phosphate buffered saline
(PBS), lysed with 250 ml per well of 1x reporter lysis buffer
(Promega), and freeze-thawed once. After samples were centri-
fuged at 13,0006g for 5 min, 20 ml and 50 ml of cell lysates were
used to determine luciferase and b-gal in the extracts. The
expression vector pcDNA3.1 was set at unity and the values for
different promoters compared to this control as fold induction.
Electrophoretic Mobility Shift Assay
Nuclear extracts were prepared as described [45]. Electropho-
retic mobility shift assay was performed using a digoxigenin (DIG)
gel shift kit (Roche Applied Science, Indianapolis, IN). Synthetic
oligonucleotides were annealed with their complementary strand
and labeled with DIG at the 39end[26]. Labeled DNA probes were
incubated with 7.5 mg of nuclear extract for 20 min at 4uC.
Poly(dI-dC) was added to reduce nonspecific binding. For
competition assays, labeled probes were incubated with increasing
amounts of cold unlabeled wild type or mutant double-stranded
oligonucleotides (50x, 100x) and nuclear extract. Protein-DNA
complexes were separated on a 6% non-denaturing polyacryl-
amide gel in 0.5x Tris-borate-EDTA buffer, transferred to nylon
membrane, and probed with 1:15,000 dilution of antidigoxigenin
antibody conjugated to alkaline phosphatase (Roche Applied
Science, Indianapolis, IN). Bands were visualized by Western Blue
stabilized substrate (Promega). Gels were scanned using the Epson
Perfection 4990 Scanner (Epson America, Long Beach, CA) and
processed using Silverfast Launcher Software V2.1.3 (LaserSoft
Imaging, Sarasota, FL). Figures were prepared for publication
using Adobe Photoshop CS, Version 8.0 for the Macinosh.
siRNA Transfection
siRNA duplexes targeting ELK1 were purchased from Ambion
(Austin, TX). Silencer negative control siRNA and siRNA for b-
actin as a positive control were used. HEK293T cells at 50–60%
confluence were transfected with siRNA duplexes at a final
concentration of 60 nM in complete DMEM (Invitrogen) using
3 ml of siPORT Amine transfection reagent (Ambion). The
mixture of siRNA, plasmid DNAs and transfection reagent were
prepared in 200 ml of serum-free DMEM. The first transfection
mixture contained siRNA, plasmid DNAs and transfection
reagent. Twenty-four hrs later, the transfection procedure was
repeated without plasmid DNAs, and cells were incubated for
another 48 hrs in normoxia and cell lysates were prepared.
Immunoblotting
Whole cell lysates were prepared from HEK293T cells using an
M-PER extraction kit (Pierce, Rockford, IL). Five to 20 mgo f
lysate were electrophoresed on pre-cast 4–12% Tris-Bis NuPAGE
(Invitrogen) and transferred to nitrocellulose. The membrane was
blocked with 5% w/v nonfat dry milk in 1xTBST(10 mM Tris-
Hcl, pH 8.0, 150 mM NaCl, and 0.05% Tween 20) overnight at
40uC. Blots were then incubated with monoclonal antibody to
GADPH or to b-actin, or rabbit polyclonal antibody to ELK1
(Santa Cruz Biotechnology, Santa Cruz, CA). After 1 hr
incubation with appropriate secondary antibody conjugated to
alkaline phosphatase (Promega), bands were visualized with
Western Blue stabilized substrate (Promega). Membranes were
scanned and the images processed as described above.
Quantitative Real-Time PCR
Total RNA was extracted from HEK293T cells 48 hrs post
transfection with RNAeasy kit (Qiagen, Valencia, CA). Five mg
each of total RNA was treated with RNase free DNaseI (Ambion)
[11]. First-strand cDNA was synthesized from 820 ng of total
RNA using Roche First Strand cDNA Synthesis kit (Roche
Applied Science). For real-time PCR experiments, 41 ng of RNA
(start) was amplified in 2xSYBR PCR master mix using TF-
Stepone RT PCR System (PE applied Biosystems, Branchburg,
NJ) with the following primers (shown in 59 to 39 direction): for
Actin, CCTTCCTGGGCATGGAGT and CAGGGCAGT-
GATCTCCTTCT; for GAPDH, CCAGCCGAGCCACATC-
GCTC and ATGAGCCCCAGCCTTCTCCAT; for ELK1, CC-
TGTCTGCGTTTTTGGATGTG and TGTCTGAGAGAAA-
GGTTGGGGG. Samples were incubated at 95uC for 10 minutes,
followed by 40 cycles, each consisting of 95uC for 15 seconds,
60uC for 1 minute. Melting curves were generated after each run
to confirm amplification of specific transcripts. All quantifications
were normalized to human b-actin. Standard curves were
obtained for each primer pair with serial dilutions of cDNA
templates. Real time PCR reactions were performed in triplicate
and each experiment repeated three times.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation assay was performed using the
EZ-Magna chip
TM A chromatin immunoprecipitation kit (Milli-
pore, USA) following manufacturer9s instructions. Briefly, 293T
cells (10
6) were transfected with HIF-2a, HIF-1a, or Elk-1
expression vectors (GeneCopoeia Inc. Rockville MD). At 36 h
post-transfection, cells were cross-linked with formaldehyde at a
final concentration of 1% at room temperature for 10 min. The
unreacted formaldehyde was quenched using 2M glycine for
5 min at room temperature before harvest. Cells were scraped and
resuspended in lysis buffer containing protease inhibitors. Soluble
Induction of PTPRZ1 by HIF-2a
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sonicator (Osonica, LLC, Newtown, CT, USA) to an average
DNA length of 200 to 1000 bp. Approximately 3610
5 cell-
equivalents of the pre-cleared chromatin was immunoprecipitated
with 5 mg of anti-HIF1a, anti-HIF2a (Novus Biologicals), anti-Elk-
1 or normal IgG (Santa Cruz Biotechnology) antibody together
with protein A magnetic beads for overnight at 4uC on a rotating
platform. 10% of the pre-cleared lysate was set aside as input
control. Immune complexes were washed with high salt immune
complex buffer, low salt immune complex buffer, lithium chloride
immune complex buffer, and TE buffer each for 4 min at room
temperature on a rotating platform. The immune complexes were
eluted and the DNA-protein cross-linking was reversed by heating
at 62uC for 2 h with constant shaking. The chromatin was purified
using spin columns provided with the kit and analyzed by PCR
using the specific primers (PTPRZ1: 59-TCC AGA TTA TTC
CTC TCT CGC-39,5 9-AGA GGA GCT GAA TGC AAG CG-
39); the region spanned by these primers includes HRE4, HRE5,
EBS4, and EBS5. PCR products were electrophoresed with a 2%
agarose gel stained with ethidium bromide.
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